Market Data 
Markets
Replies to post #10674 on ProtoKinetix Inc (PKTX)
04/15/21 6:03 PM
04/15/21 6:08 PM
04/15/21 6:10 PM
04/16/21 7:15 AM
At Catalent, we are keenly aware that every biologic drug has different needs and challenges. That is why we provide comprehensive solutions from development and biomanufacturing to fill/finish and packaging for new biological entities, cell and gene therapies, biosimilars, sterile injectables and antibody-drug conjugates.
As a global biologics leader with state-of-the-art facilities in Europe and North America, we have experience working with customers of all sizes from top global multinational pharma to small and virtual companies. Our advanced technologies including GPEx®, SMARTag®, and adeno-associated virus (AAV) vectors can help you create next generation therapies. Our OneBio® integrated offering leverages Catalent’s Follow the Molecule® development and manufacturing approach to provide you accelerated and integrated solutions from development to supply.
We attract some of the best experts in the industry, and that’s why our employees are committed to driving service excellence and actively contributing to a “Patient-First” culture, putting the patient at the center of everything we do.
Catalent’s commitment to quality can be seen throughout our organization, from our inspection-ready sites to our efforts to continually refine and improve the type and scope of services we can provide our customers. We pride ourselves on our ability to offer our customers biologic development and manufacturing solutions that are innovative and flexible and support them in their pursuit of significant and potentially life-changing and life-saving medications.
